Сергей Вялов - О чем молчит печень. Как уловить сигналы самого крупного внутреннего органа, который предпочитает оставаться в тени

22. [Guideline] Terrault N.A., Lok A.S.F., McMahon B.J. et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology . 2018 Apr. 67 (4): 1560–1599.

23. [Guideline] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol . 2017 Aug. 67 (2): 370–398.

24. Schiff E.R., Lee S.S., Chao Y.C. et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol . 2011 Mar. 9 (3): 274–276.

25. Hoofnagle J.H. Reactivation of hepatitis B. Hepatology . 2009 May. 49(5 suppl):S156-65.

26. Bean P. Latest discoveries on the infection and coinfection with hepatitis D virus. Am Clin Lab . 2002 Jun. 21 (5): 25–27.

27. Xiridou M., Borkent-Raven B., Hulshof J., Wallinga J. How hepatitis D virus can hinder the control of hepatitis B virus. PLoS One . 2009. 4 (4): e5247.

28. Abbas Z., Afzal R. Life cycle and pathogenesis of hepatitis D virus: a review. World J Hepatol . 2013 Dec 27. 5 (12): 666–675.

29. Bahcecioglu I.H., Sahin A. Treatment of delta hepatitis: today and in the future – a review. Infect Dis (Lond) . 2017 Apr. 49 (4): 241–250.

30. Alfaiate D., Deny P., Durantel D. Hepatitis delta virus: from biological and medical aspects to current and investigational therapeutic options. Antiviral Res . 2015 Oct. 122: 112–129.

31. Goyal A., Murray J.M. Recognizing the impact of endemic hepatitis D virus on hepatitis B virus eradication. Theor Popul Biol . 2016 Dec. 112: 60–69.

1. Strassburg C.P., Manns M.P. Treatment of autoimmune hepatitis. Semin Liver Dis . 2009 Aug. 29 (3): 273–285.

2. Longhi M.S, Ma. Y., Mieli-Vergani G., Vergani D. Aetiopathogenesis of autoimmune hepatitis. J Autoimmun . 2010 Feb. 34 (1): 7–14.

3. Vento S., Cainelli F. Is there a role for viruses in triggering autoimmune hepatitis? Autoimmun Rev . 2004 Jan. 3 (1): 61–69.

4. Umemura T., Ota M. Genetic factors affect the etiology, clinical characteristics and outcome of autoimmune hepatitis. Clin J Gastroenterol . 2015 Dec. 8 (6): 360–366.

5. Czaja A.J. Diagnosis and management of autoimmune hepatitis. Clin Liver Dis . 2015 Feb. 19 (1): 57–79.

6. [Guideline] Gleeson D., Heneghan M.A. British Society of Gastroenterology. British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis. Gut . 2011 Dec. 60 (12): 1611–1629.

7. Floreani A., Rizzotto E.R., Ferrara F. et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol . 2005 Jul. 100 (7): 1516–1522.

8. [Guideline] Manns M.P., Czaja A.J., Gorham J.D. et al. Diagnosis and management of autoimmune hepatitis. Hepatology . 2010 Jun. 51 (6): 2193–2213.

1. Gottesman L.E., Del Vecchio M.T., Aronoff S.C. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatr . 2015 Nov 20. 15: 192.

2. Gotze T., Blessing H., Grillhosl C., Gerner P., Hoerning A. Neonatal cholestasis – differential diagnoses, current diagnostic procedures, and treatment. Front Pediatr . 2015. 3: 43.

3. Davis A.R., Rosenthal P., Escobar G.J., Newman T.B. Interpreting conjugated bilirubin levels in newborns. J Pediatr . 2011 Apr. 158 (4): 562–565.e1.

4. Memon N., Weinberger B.I., Hegyi T., Aleksunes L.M. Inherited disorders of bilirubin clearance. Pediatr Res . 2016 Mar. 79 (3): 378–386.

5. van Dijk R., Beuers U., Bosma P.J. Gene replacement therapy for genetic hepatocellular jaundice. Clin Rev Allergy Immunol . 2015 Jun. 48 (2–3): 243–253.

6. Sticova E., Jirsa M. New insights in bilirubin metabolism and their clinical implications. World J Gastroenterol . 2013 Oct 14. 19 (38): 6398–6407.

1. Stanley S.L. Jr. Amoebiasis. Lancet . 2003 Mar 22. 361 (9362): 1025–1034.

2. Acuna-Soto R., Maguire J.H., Wirth D.F. Gender distribution in asymptomatic and invasive amebiasis. Am J Gastroenterol . 2000 May. 95 (5): 1277–1283.

3. Ralston K.S., Petri WA Jr. Tissue destruction and invasion by Entamoeba histolytica. Trends Parasitol . 2011 Jun. 27 (6): 254–263.

4. Tanyuksel M., Petri W.A. Jr. Laboratory diagnosis of amebiasis. Clin Microbiol Rev . 2003 Oct. 16 (4): 713–729.

5. Maltz G., Knauer C.M. Amebic liver abscess: a 15-year experience. Am J Gastroenterol . 1991 Jun. 86 (6): 704–710.

6. [Guideline] World Health Organization. Preventive chemotherapy to control soil-transmitted helminth infections in at-risk population groups.

7. Dold C., Holland C.V. Ascaris and ascariasis. Microbes Infect . 2011 Jul. 13 (7): 632–637.

8. Gangopadhyay A.N., Upadhyaya V.D., Gupta D.K. et al. Conservative treatment for round worm intestinal obstruction. Indian J Pediatr . 2007 Dec. 74 (12): 1085–1087.

9. Das A.K. Hepatic and biliary ascariasis. J Glob Infect Dis . 2014 Apr. 6 (2): 65–72.

10. Wani I. Gallbladder ascariasis. Turk J Gastroenterol . 2011. 22 (2): 178–182.

11. [Guideline] Brunetti E., Kern P., Vuitton D.A, Expert consensus for the diagnosis and treatment of cystic and alveolar echinococcosis in humans. Acta Trop . 2010 Apr. 114 (1): 1–16.

12. Macpherson C.N., Bartholomot B., Frider B. Application of ultrasound in diagnosis, treatment, epidemiology, public health and control of Echinococcus granulosus and E. multilocularis. Parasitology . 2003. 127 Suppl: S21–35.

13. Junghanss T., da Silva A.M., Horton J., Chiodini P.L., Brunetti E. Clinical management of cystic echinococcosis: state of the art, problems, and perspectives. Am J Trop Med Hyg . 2008 Sep. 79 (3): 301–311.

14. McManus D.P., Zhang W., Li J., Bartley P.B. Echinococcosis. Lancet . 2003 Oct 18. 362 (9392): 1295–1304.

15. Filippou D, Tselepis D, Filippou G, Papadopoulos V. Advances in liver echinococcosis: diagnosis and treatment. Clin Gastroenterol Hepatol . 2007 Feb. 5 (2): 152–159.

16. Parija S.C. Textbook of Medical Parasitology. Protozoology and Helminthology . 4 ed. New Delhi: All India: Publishers and Distributers; 2013.

17. Sakru N., Korkmaz M., Demirci M., Kuman A. Ok U.Z. Fasciola hepatica infection in echinococcosis suspected cases. Turkiye Parazitol Derg . 2011. 35 (2): 77–80.

18. Garcia L.S. Diagnostic Medical Parasitology . 5th ed. Washington, D.C: ASM Press; 2007.

19. Ubeira F.M., Muino L., Valero M.A., Periago M.V., Perez-Crespo I., Mezo M. MM3-ELISA detection of Fasciola hepatica coproantigens in preserved human stool samples. Am J Trop Med Hyg . 2009 Jul. 81 (1): 156–162.

20. Ezzat R.F., Karboli T.A., Kasnazani K.A., Hamawandi A.M.. Endoscopic management of biliary fascioliasis: a case report. J Med Case Rep . 2010 Mar 6. 4: 83.

1. Fleming R.E., Britton R.S., Waheed A. et al. Pathogenesis of hereditary hemochromatosis. Clin Liver Dis . 2004 Nov. 8 (4): 755–773, vii.

2. Adams P.C., Barton J.C. Haemochromatosis. Lancet . 2007 Dec 1. 370 (9602): 1855–1860.

3. Gattermann N. The treatment of secondary hemochromatosis. Dtsch Arztebl Int . 2009 Jul. 106 (30): 499–504, I.